Skip to main content
Simcere Pharmaceutical Group Limited logo

Simcere Pharmaceutical Group Limited — Investor Relations & Filings

Ticker · S2P ISIN · HK0000658531 HKEX Manufacturing
Open in API
Filings indexed 577 across all filing types
Latest filing 2023-05-02 Regulatory Filings
Country CN China
Listing HKEX S2P

About Simcere Pharmaceutical Group Limited

https://www.simcere.com/en/

Simcere Pharmaceutical Group Limited is an R&D-driven pharmaceutical company specializing in the discovery, development, and commercialization of innovative and branded generic prescription drugs. The company strategically focuses on core therapeutic areas, including neuroscience, anti-oncology, and inflammatory diseases. Simcere emphasizes synergistic innovation, evidenced by its development and launch of multiple Category I innovative pharmaceuticals and its strategic collaborations with global partners to advance novel treatments. These partnerships aim to address significant unmet medical needs and expand the company's portfolio across specialized disease areas.

Recent filings

Filing Released Lang Actions
VOLUNTARY ANNOUNCEMENT - THE NEW INDICATION OF SANBEXIN (EDARAVONE AND DEXBORNEOL CONCENTRATED SOLUTION FOR INJECTION) OBTAINED THE CLINICAL TRIAL APPROVAL ISSUED BY THE NATIONAL MEDICAL PRODUCTS ADMI
Regulatory Filings Classification · 95% confidence The document is a voluntary announcement by Simcere Pharmaceutical Group Limited regarding the clinical trial approval for a new indication of their drug Sanbexin. It is an announcement about a business development event, specifically the approval of a clinical trial by a regulatory authority (National Medical Products Administration). The document does not contain financial data, financial results, or detailed report content. It is relatively short (4301 characters) and serves to inform shareholders and investors about a new clinical trial approval, which is a business update rather than a financial report or regulatory filing. It does not fit into categories like Annual Report, Interim Report, Earnings Release, or Regulatory Filings related to financial or governance matters. It is best classified as a Regulatory Filings (RNS) type, which is the fallback for miscellaneous announcements that do not fit other categories.
2023-05-02 English
NOTIFICATION LETTER AND REQUEST FORM TO NON-REGISTERED SHAREHOLDERS: NOTICE OF PUBLICATION OF 2022 ANNUAL REPORT AND ENVIRONMENTAL, SOCIAL AND GOVERNANCE REPORT
Report Publication Announcement Classification · 95% confidence The document is a notification letter dated April 17, 2023, from Simcere Pharmaceutical Group Limited informing non-registered shareholders about the publication of the Annual Report 2022 and the Environment, Social and Governance (ESG) Report. It provides instructions on how shareholders can access these reports electronically or request printed copies. The letter explicitly states that the reports are available on the company's and HKEX's websites and offers a request form for printed versions. The document itself does not contain the actual annual report or ESG report content but is an announcement of their publication and availability. The document length is 8047 characters, which is relatively short and consistent with a notification letter rather than a full report. According to the classification rules, such a document is classified as a Report Publication Announcement (RPA) because it announces the availability of the annual and ESG reports but does not contain the reports themselves.
2023-04-17 English
2022 ANNUAL REPORT
Annual Report Classification · 100% confidence The document is titled 'ANNUAL REPORT 2022' and contains detailed sections typical of an annual report, including Corporate Information, Financial Highlights, Company Overview, Chairman's Statement, Management Discussion and Analysis, Directors' Report, Corporate Governance Report, Biographies of Directors and Senior Management, Independent Auditor's Report, and full financial statements such as Consolidated Statement of Profit or Loss, Statement of Financial Position, Changes in Equity, Cash Flow Statement, and Notes to the Financial Statements. The length is substantial (15,000 characters), indicating it is the full report rather than a brief announcement. The content includes comprehensive financial data, management commentary, and governance information, consistent with an official yearly report covering company activity and full financial performance. Therefore, the document fits the definition of an Annual Report (10-K). FY 2022
2023-04-17 English
2022 ENVIRONMENTAL, SOCIAL AND GOVERNANCE REPORT
Environmental & Social Information Classification · 100% confidence The document is titled 'Environmental, Social and Governance Report' and contains detailed sections on ESG governance, environmental management, social welfare, and corporate governance practices. It covers the reporting period of January 1 to December 31, 2022, and is prepared in accordance with ESG reporting guidelines under the Hong Kong Stock Exchange rules. The content focuses on sustainability, social responsibility, environmental impact, and governance structures rather than financial performance or audit results. Therefore, it fits the category of Environmental & Social Information (ESG) report rather than an annual report, audit report, or other financial filings.
2023-04-17 English
Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 March 2023
Regulatory Filings Classification · 95% confidence The document is a monthly return filing related to movements in securities, specifically issued shares and share capital details for Simcere Pharmaceutical Group Limited. It is addressed to the Hong Kong Exchanges and Clearing Limited and includes detailed tables on share movements, share options, and confirmations. The document does not contain financial statements, earnings data, or management discussion. It is a regulatory compliance filing reporting share capital and share issuance movements rather than a financial report or announcement of voting results. The document length is about 5,000 characters, and it is a formal regulatory submission. This type of document fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories such as capital changes (SHA) or director dealings (DIRS). Although it relates to share capital, it is a monthly return report rather than a direct announcement of a share issue or capital change event. Therefore, the most appropriate classification is Regulatory Filings (RNS).
2023-04-06 English
LIST OF DIRECTORS AND THEIR ROLES AND FUNCTIONS
Board/Management Information Classification · 95% confidence The document is a list of directors and their roles and functions within the company, including details about board committees. It does not contain financial data, audit results, or meeting minutes. It is an announcement related to board composition and governance structure. Therefore, it fits best under Board/Management Information (MANG). The document length is short and focused solely on board members and committees, confirming it is not a full report or presentation.
2023-03-31 English

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.